uploads/2018/02/heartbeat-1892826_1280.jpg

What Analysts Recommend for Abiomed and Peers in February 2018

By

Updated

Company overview

Abiomed (ABMD) is a supplier of mechanical circulatory support devices and offers a continuum of care to heart failure patients. Abiomed develops, manufactures, and commercializes products designed to improve the blood flow and perform the pumping function of the heart. These products are used in cardiac catheterization by interventional cardiologists and in heart surgery by heart surgeons.

Article continues below advertisement

Analysts’ recommendations

Of the ten analysts covering Abiomed (ABMD) in February 2018, five analysts have given the stock a “strong buy” rating, three analysts have given it a “buy” rating, while two analysts have given it a “hold” rating. The mean rating for the stock is 1.7 with a target price of $281.22.

Peer ratings

All of the eight analysts covering NxStage Medical (NXTM) in February 2018 have given the stock a “hold” rating. The mean rating for the stock is three with a target price of $29.88.

Of the 17 analysts covering Baxter International (BAX) in February 2018, ten analysts have given the stock a “buy” or higher rating. Six analysts have given it a “hold” rating, while one analyst has given it a “sell” rating. The mean rating for the stock is 2.3 with a target price of $75.27.

Of the 16 analysts covering Insulet (PODD) in February 2018, ten analysts have given the stock a “buy” or a higher rating, while six analysts have given it a “hold” rating. The mean rating for the stock is 2.1 with a target price of $74.38.

In the next part of the series, we’ll take a look at Abiomed’s product pipeline.

Advertisement

More From Market Realist